Enterprise Value to EBITDA Ratio: CG Oncology, Inc. (CGON)

CG Oncology (CGON) - corporate logo

The EV/EBITDA chart demonstrates CG Oncology, Inc. (CGON) dependence on contract manufacturing organizations for drug production, where the value of 0.00 serves as the current metric. The development of bladder cancer immunotherapy is based on alliances with clinics, while future patents will provide the company with pricing power in a monopoly market segment.

CGON CG Oncology Inc: Business Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/16/2026

Summary analytical data breakdowns for CG Oncology (CGON)

- current price and projected stock value:
- company stock exchange capitalization indicators:
Basic company analysis:CG Oncology, Inc. (CGON)
Product sample of cgoncology.com

The multiple compares the total enterprise value (market capitalization plus net debt) to earnings before interest, taxes, depreciation, and amortization, allowing for an assessment of the real value of assets without the influence of tax policy. By analyzing the EV/EBITDA valuation trend, an investor can compare market expectations for innovative bladder cancer treatments with the capital management efficiency of CG Oncology, Inc. (CGON) management following the IPO.

Key competitors

BeiGene Oncology - Enterprise Value to EBITDA Ratio|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|UroGen (URGN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Bicara Bio - Business Value to Operating Income Before Depreciation|PSNL (Personalis Inc) - EV/EBITDA Multiple|Company Value to EBITDA Erasca, Inc. ERAS|EV/EBITDA Multiple DCTH|YMAB - Company Value to EBITDA|Aura Biosciences Inc - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Candel Therapeutics CADL|accuray.com - EV/EBITDA Multiple|SLS: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ACTU (actuatetherapeutics.com) - Enterprise Value to EBITDA Ratio|CTOR - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization tuhurabio.com|EV/EBITDA Multiple Protara Tx|Enterprise Value to EBITDA Ratio FATE (Fate Therapeutics Corp)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization WHWK (Aadi Bioscience)|TScan Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|Champions Oncology (CSBR) - Company Value to EBITDA|XBiotech - EV/EBITDA Multiple|CEL-SCI (CVM) - Enterprise Value to EBITDA Ratio|OS Therapies Inc (OSTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|radiopharmtheranostics.com - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Artiva Biotherapeutics Inc.|Company Value to EBITDA Adlai Nortye Ltd. ANL|EV/EBITDA Multiple VERU|TPST - Company Value to EBITDA|EV/EBITDA Multiple XLO (Xilio Therapeutics)|RENB - Enterprise Value to EBITDA Ratio|muraloncology.com - EV/EBITDA Multiple|KAPA - EV/EBITDA Multiple|OKUR: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio GDTC (CytoMed Therapeutics Ltd)|CRIS (curis.com) - EV/EBITDA Multiple|Apollomics, Inc. (APLM) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio THAR (Tharimmune, Inc.)|ADVB (Advanced Biomed) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple GNPX (Genprex Inc)|calidibio.com (CLDI) - Company Value to EBITDA|sunshinebiopharma.com - EV/EBITDA Multiple|Company Value to EBITDA Xenetic Biosciences, Inc.|SLRX (Salarius Pharmaceuticals) - Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Ratio Purple Biotech Ltd.|AONC (American Oncology Network Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio BeOne Medicines (BGNE)|EV/EBITDA Multiple CKPT|ELEV - Company Value to EBITDA|iCAD Inc. - Enterprise Value to EBITDA Ratio|IKNA: Enterprise Value to Operating Income Before Depreciation|Notable Labs Ltd - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation VIRX (Viracta Therapeutics Inc.)|MorphoSys AG (MOR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio NAYA Biosciences|AAPGV (ascentage.com) - EV/EBITDA Multiple